FILSPARI
Live / Registered — Registered (as of 02 May 2023)
What this means for you
Registered since 02 May 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90818374
- Registration number
- 7044077
- Mark type
- Stylized text
- Filed
- 08 Jul 2021
- Published for opposition
- 03 May 2022
- Registered
- 02 May 2023
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of kidney disease; pharmaceutical preparations for the treatment of focal segmental glomerulosclerosis (FSGS); pharmaceutical preparations for the treatment of Immunoglobulin A Nephropathy (IgAN); pharmaceutical preparations for the treatment of Alport Syndrome
Owner
- Travere Therapeutics, Inc., San Diego, CA, US
- Travere Therapeutics, Inc., San Diego, CA, US
- Travere Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 02 May 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 02 May 2023 — REGISTERED-PRINCIPAL REGISTER
- 31 Mar 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 30 Mar 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 09 Mar 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Feb 2023 — USE AMENDMENT FILED
- 09 Mar 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Feb 2023 — TEAS STATEMENT OF USE RECEIVED
- 22 Dec 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Dec 2022 — SOU EXTENSION 1 GRANTED
- 20 Dec 2022 — SOU EXTENSION 1 FILED
- 20 Dec 2022 — SOU TEAS EXTENSION RECEIVED
- 28 Jun 2022 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 May 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 May 2022 — PUBLISHED FOR OPPOSITION